Kerostx
NASDAQ: KROSUnicorn · $1.1BLexington, US · Founded 2016 · 125 employees on LinkedIn · 4 known investors
Find your way into Kerostx
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.
Founders & leadership
Kerostx was founded in 2016 by Jasbir S. Seehra and Jasbir Seehra.
Board
Investors · 4
Reported raises · per SEC filings
Form D private placements$78.5M disclosed across 3 of 5 rounds · 1900–2020
▶$56MraisedMar 2020 · 20 investors · OtherRule 506(b)
- Keith RegnanteExecutive Officer
- Jenn LacheyExecutive Officer
- Claudia OrdonezExecutive Officer
- Jasbir SeehraExecutive Officer, Director
- Nima FarzanDirector
- Alon LazarusDirector
- Ran NussbaumDirector
- Zafrira AvnurDirector
- Carl GordonDirector
- Julius KnowlesDirector
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$11.5MraisedNov 2018 · 9 investors · BiotechnologyRule 506(b)
- Alon LazarusDirector
- Ran NussbaumDirector
- Julius KnowlesDirector
- Zafrira AvnurDirector
- Jasbir S. SeehraExecutive Officer, Director
- Ohad HammerDirector
- Offering amount
- $23M
- Amount sold
- $11.5M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$11MraisedNov 2017 · 7 investors · BiotechnologyRule 506(b)
- Jasbir S. SeehraExecutive Officer, Director
- Julius KnowlesDirector
- Alon LazarusDirector
- Ohad HammerDirector
- Ran NussbaumDirector
- Offering amount
- $11M
- Amount sold
- $11M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Keros Therapeutics Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Kerostx do?
- Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.
- Who founded Kerostx?
- Kerostx was founded by Jasbir S. Seehra, Jasbir Seehra in 2016.
- Who are Kerostx's investors?
- Kerostx's investors include Arkin Capital, Foresite Capital, OrbiMed, Pontifax Venture Capital.
- How much funding has Kerostx raised?
- Kerostx has disclosed $78.5M raised across 3 of its 5 known rounds.
- Where is Kerostx headquartered?
- Kerostx is headquartered in Lexington, US.